ChemicalBook >> CAS DataBase List >>GSK2656157

GSK2656157

CAS No.
1337532-29-2
Chemical Name:
GSK2656157
Synonyms
5-[4-Fluoro-1-[(6-methyl-2-pyridinyl)acetyl]-2,3-dihydro-1H-indol-5-yl]-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;CS-804;GSK2656157;GSK2656157 USP/EP/BP;GSK2656157(GSK-2656157);PERK inhibitor GS2656157;PERK inhibitor GSK2656157;4-Dihydroxybenzoic acid methyl ester;GSK2656157; GSK 2656157; GSK-2656157.;1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoroindolin-1-yl)-2-(6-methylpyrid
CBNumber:
CB62664486
Molecular Formula:
C23H21FN6O
Molecular Weight:
416.45
MDL Number:
MFCD27997885
MOL File:
1337532-29-2.mol
MSDS File:
SDS
Last updated:2024-11-19 23:02:33

GSK2656157 Properties

Melting point 194-196°C
Boiling point 744.6±60.0 °C(Predicted)
Density 1.43±0.1 g/cm3(Predicted)
storage temp. -20°C
solubility Soluble in DMSO (10 mg/ml with warming)
form solid
pka 5.32±0.30(Predicted)
color White
Stability Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS07
Signal word  Warning
Hazard statements  H302
Precautionary statements  P264-P270-P301+P312-P330-P501
NFPA 704
0
2 0

GSK2656157 price More Price(30)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 17372 GSK2656157 ≥98% 1337532-29-2 5mg $47 2024-03-01 Buy
Cayman Chemical 17372 GSK2656157 ≥98% 1337532-29-2 10mg $87 2024-03-01 Buy
Cayman Chemical 17372 GSK2656157 ≥98% 1337532-29-2 25mg $206 2024-03-01 Buy
Cayman Chemical 17372 GSK2656157 ≥98% 1337532-29-2 50mg $360 2024-03-01 Buy
TRC G797515 GSK2656157 1337532-29-2 100mg $725 2021-12-16 Buy
Product number Packaging Price Buy
17372 5mg $47 Buy
17372 10mg $87 Buy
17372 25mg $206 Buy
17372 50mg $360 Buy
G797515 100mg $725 Buy

GSK2656157 Chemical Properties,Uses,Production

Description

GSK2656157 (1337532-29-2) is a potent (IC50 = 0.9 nM) and selective (over 300 kinases) inhibitor of protein kinase RNA-like endoplasmic reticulum kinase (PERK).1,2? Inhibited growth of multiple human tumor xenografts in mice. GSK2656157 has also been found to potently inhibit RIPK1 (IC50 = 69 nM) and TNF-mediated RIPK1 kinase-dependent cell death in mouse embryonic fibroblasts.3 It prevented the loss of dendritic spines and rescued memory deficits after traumatic brain injury.4? GSK2656157 also enhanced glucose-stimulated insulin secretion in a mouse model of type 2 diabetes mellitus.5

Uses

GSK2656157 is an ATP-competitive and highly selective inhibitor of PKR-like endoplasmic reticulum kinase (PERK) enzyme activity. GSK2656157 also has anti-tumor and anti-angiogenic activity.

Definition

ChEBI: GSK2656157 is a pyrrolopyrimidine that is 7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine which has been substituted at position 5 by a 4-fluoro-2,3-dihydro-1H-indol-5-yl group, the nitrogen of which has been acylated by a (6-methylpyridin-2-yl)acetyl group. An orally bioavailable PERK inhibitor. It has a role as an EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor, a PERK inhibitor and an antineoplastic agent. It is a pyrrolopyrimidine, a biaryl, a member of indoles, a member of methylpyridines, an organofluorine compound and a tertiary carboxamide.

in vivo

assay shows that a single 50 mg/kg oral dose of gsk2656157 can completely inhibit the thr980 phosphorylation of endogenous pancreatic perk in mice. furthermore, gsk2656157 causes dose-dependent inhibition of tumor growth in human tumor xenograft models of pancreatic cancer (bxpc3, hpac and capan2) and multiple myeloma (nci-h929). among these cancers, the capan2 tumor is most sensitive [1].

References

Atkins et al. (2013) Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity; Cancer Res. 73 1993 Axten et al. (2014) Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development; ACS Med. Chem. Lett. 4 964 Rojas-Rivera et al. (2017) When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157; Cell Death Differ. 24 1100 Sen et al. (2017) Activation of PERK Elicits Memory Impairment through Inactivation of CREB and Downregulation of PSD95 After Traumatic Brain Injury; Neurosci. 37 5900 Kim et al. (2019) Specific PERK inhibitors enhanced glucose-stimulated insulin secretion in a mouse model of type 2 diabetes; Metabolism, 97 87

GSK2656157 Preparation Products And Raw materials

Raw materials

Preparation Products

GSK2656157 Suppliers

Global( 98)Suppliers
Supplier Tel Email Country ProdList Advantage
Hubei Jusheng Technology Co.,Ltd.
18871490254 linda@hubeijusheng.com CHINA 28172 58
career henan chemical co
+86-0371-86658258 +8613203830695 factory@coreychem.com China 29811 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000 marketing@targetmol.com United States 32161 58
HANGZHOU CLAP TECHNOLOGY CO.,LTD
86-571-88216897,88216896 13588875226 sales@hzclap.com CHINA 6312 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250 1026@dideu.com China 22785 58
InvivoChem
+1-708-310-1919 +1-13798911105 sales@invivochem.cn United States 6391 58
LEAP CHEM CO., LTD.
+86-852-30606658 market18@leapchem.com China 24727 58
ShenZhen Trendseen Biological Technology Co.,Ltd.
13417589054 trendseenbio@gmail.com China 11681 58
Aladdin Scientific
+1-+1(833)-552-7181 sales@aladdinsci.com United States 57505 58
Amadis Chemical Company Limited
571-89925085 sales@amadischem.com China 131957 58

View Lastest Price from GSK2656157 manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
GSK2656157 pictures 2024-11-19 GSK2656157
1337532-29-2
US $32.00-74.00 / mg 99.89% 10g TargetMol Chemicals Inc.
	GSK2656157 pictures 2020-01-14 GSK2656157
1337532-29-2
US $1.00 / g 1g 99% 200kg Career Henan Chemical Co
  • GSK2656157 pictures
  • GSK2656157
    1337532-29-2
  • US $32.00-74.00 / mg
  • 99.89%
  • TargetMol Chemicals Inc.
  • 	GSK2656157 pictures
  • GSK2656157
    1337532-29-2
  • US $1.00 / g
  • 99%
  • Career Henan Chemical Co

GSK2656157 Spectrum

GSK2656157 1-(5-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoroindolin-1-yl)-2-(6-methylpyridin-2-yl)ethanone 5-[4-Fluoro-1-[(6-methyl-2-pyridinyl)acetyl]-2,3-dihydro-1H-indol-5-yl]-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine GSK2656157 1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoroindolin-1-yl)-2-(6-methylpyrid GSK2656157(GSK-2656157) GSK2656157; GSK 2656157; GSK-2656157. 1-(5-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoroindolin-1-yl)-2-(6-methylpyridin-2-yl)ethan-1-one GSK2656157 PERK inhibitor GS2656157 CS-804 Ethanone, 1-[5-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoro-2,3-dihydro-1H-indol-1-yl]-2-(6-methyl-2-pyridinyl)- GSK2656157 USP/EP/BP PERK inhibitor GSK2656157 4-Dihydroxybenzoic acid methyl ester 5-[4-Fluoro-1-[(6-methyl-2-pyridinyl)acetyl]-2,3-dihydro-1H-indol-5-yl]-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoro-2,3-dihydroindol-1-yl]-2-(6-methylpyridin-2-yl)ethanone 1337532-29-2 C23H21FN6O Inhibitors